Imatinib mesylate in the treatment of unresectable and/or metastatic gastrointestinal stromal tumors
- VernacularTitle:甲磺酸伊马替尼治疗不能切除和/或转移的胃肠道间质瘤的临床分析
- Author:
Wen ZHANG
;
Xichun HU
;
Hongfen LU
;
Al ET
- Publication Type:Journal Article
- Keywords:
gastrointestinal stromal tumors;
Imatinib mesylate;
chemotherapy
- From:
China Oncology
2001;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To evaluate the efficacy and toxicity of imatinib mesylate (STI571) in the treatment of unresectable and/or metastatic gastrointestinal stromal tumors (GIST).Methods:Ten patients with unresectable and/or metastatic GIST received imatinib at doses of 400 mg qd.Results:Among 9 evaluable patients, 4 achieved a partial response and 4 had stable disease. Ten patients were evaluable for toxicities. The nonhaematological toxicities included edema (mainly periorbital edema), abdominal pain, diarrhoea, nausea/vomiting, fatigue, intratumoural bleeding, intermittent muscle cramps and conjunctivitis. Myelosuppression was an infrequent side effect.Conclusions:Imatinib mesylate is an inhibitor of tyrosine kinase and has been proven to be active in patients with unresectable or metastatic GIST. Toxicity is acceptable.
